Page last updated: 2024-11-05

5-methylurapidil and Hyperhomocysteinemia

5-methylurapidil has been researched along with Hyperhomocysteinemia in 1 studies

Hyperhomocysteinemia: Condition in which the plasma levels of homocysteine and related metabolites are elevated (

Research Excerpts

ExcerptRelevanceReference
"Hyperhomocysteinemia is a known risk factor for cardiovascular diseases, but the underlying mechanisms of this pathology are complex."1.33Alpha1D-adrenoceptor-induced relaxation on rat carotid artery is impaired during the endothelial dysfunction evoked in the early stages of hyperhomocysteinemia. ( Cunha, FQ; de Andrade, CR; de Godoy, MA; de Oliveira, AM; de Souza, HP; Eberlin, MN; Fukada, SY; Haddad, R; Laurindo, FR; Olivon, VC, 2006)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
de Andrade, CR1
Fukada, SY1
Olivon, VC1
de Godoy, MA1
Haddad, R1
Eberlin, MN1
Cunha, FQ1
de Souza, HP1
Laurindo, FR1
de Oliveira, AM1

Other Studies

1 other study available for 5-methylurapidil and Hyperhomocysteinemia

ArticleYear
Alpha1D-adrenoceptor-induced relaxation on rat carotid artery is impaired during the endothelial dysfunction evoked in the early stages of hyperhomocysteinemia.
    European journal of pharmacology, 2006, Aug-14, Volume: 543, Issue:1-3

    Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Carotid Arteries; Disease Models,

2006